WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 47'5001 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 44'3101 Child (under 5 years) mortality rate: 52

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 36'290  35'950  35'605  35'255  34'901  30'736  27'693  24'537 
Births 387  387  386  385  383  334  388  362 
Surviving infants 386  385  384  383  382  332  385  358 
Pop. less than 5 years 1'929  1'944  1'940  1'941  1'940  1'793  1'931  1'794 
Pop. less than 15 years 5'796  5'744  5'712  5'691  5'678  5'890  5'732  5'585 
Female 15-49 years 8'317  8'313  8'309  8'309  8'310  7'978  7'475  6'544 

Number of reported cases

(Click for retrospective incidence data for Canada)
Diphtheria
ChartChart
  55 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  11  195  418  83  10  206  1'033  13'864 
Mumps
ChartChart
  309  65  40  92  54  88 
Pertussis
ChartChart
  3'896  3'510  1'527  1'261  4'845  4'054  8'030  2'873 
Polio*
ChartChart
 
Rubella
ChartChart
  28 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Canada)
Vaccine year result method % card seen                                                
BCG         
DTP1          96  96  99 
DTP3          91  91  91  95 
DTP4          77  77 
IPV1         
HepB_BD         
HepB3          55  55  70 
Hib3          91  91  91  95 
JapEnc         
MCV1          90  90  90  98 
MCV2          86  94 
MenA          89 
PCV1          98  98 
PCV2          97  97 
PCV3          79  79  79  97 
Pol3          91  91  91  99 
Rota1         
RotaC         
RCV1          89  89  89  98 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Canada)
DTP1
ChartChart
  96  96  96  96  99  95  96 
DTP3
ChartChart
  91  91  91  91  95  89  88 
HepB3
ChartChart
  55  55  55  55  70 
HepB_BD
 
Hib3
ChartChart
  91  91  91  91  95  88 
MCV1
ChartChart
  90  90  90  90  98  96  89 
MCV2
ChartChart
  86  88  90  92  94 
PCV3
ChartChart
  79  79  79  79  73 
Pol3
ChartChart
  91  91  91  91  99  88  88 
RCV1
ChartChart
  90  90  90  90  98  96  89 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG No BCG is on the routine childhood schedule for Nunavut & the Northwest Territories, as well as select Indigenous communties: provinces of Ontario, Quebec, Manitoba, Alberta
DTaPHibHepIPV 2, 4, 6, 12-24 months; Yes Schedules differ between provinces and territories across Canada.
DTaPHibIPV 2, 4, 6, 12-24 months; Yes Schedules differ between provinces and territories across Canada.
DTaPIPV 4-6 years; Yes Schedules differ between provinces and territories across Canada.
HepB_Adult 9-12 years (x2); HB vaccination is recommended in all provinces and territories (P/Ts) with varying schedules. Some P/Ts include HB vaccination in the infant schedule (within a hexavalent vaccine), others provide it in a school-based program.
HepB_Pediatric Yes B vaccination is recommended in all provinces and territories (P/Ts) with varying schedules. Some P/Ts include HB vaccination in the infant schedule, others provide it in a school-based program.
HPV 9-14 years (x2); Yes
Influenza_Adult >= 65 years; Yes and adults with chronic diseases, pregnant women, health care workers, and other risk groups
Influenza_Pediatric 6-59 months; Yes and children with chronic diseases
MenACWY-135 conj 12 years; Yes Age of administeration via a school-based schedule may differ. Some provinces and territories do not provide the quadrivalent vaccine, but rather a second dose of the men C vaccine in school.
MenC_conj 12 months; Yes Some provnces and territories (P/Ts) administer a first dose at 2-4 months of age and a second dose at 12 months of age. The majority of P/Ts provide one dose at 12 months of age.
MMR 12, 18 months; or 6 years; Yes Some provinces and territories administer MMR and varicella vaccines separately, other administer MMRV.
MMRV 12, 18 months-6 years; Yes Some provinces and territories administer MMR and varicella vaccines separately, other administer MMRV.
Pneumo_conj 2, 4, 6, 12-15 months; Yes 3 or 4 doses depending on adopted schedule. One territory provides the 4th dose at 18M.
Pneumo_ps >=65 years; Yes One province provides Pneu-P-23 at 50Y+ and another province provides a dose at 60Y+. The majority of provinces and territories (11/13) provide it at 65Y+.
Rotavirus 2, 4 months; No Although it is recommended by NACI (Canada's NITAG), 3 (of 13) provinces and territories do not have rotavirus vaccine program.
Tdap 14-16, >=18 years; Yes Schedules differ between provinces and territories across Canada.
Varicella 12 months; 18 months - 6 years; Yes Some provinces and territories administer MMR and varicella vaccines separately, other administer MMRV.
Zoster 65-70 years; No Province of Ontario only

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR   Yes    Yes  Yes  Yes   
What years does the MYP cover? number           2004-2009   
Nº of districts with microplans that include activities to raise immunization coverage number       13  13  13   

System performance

Total Nº districts in country number              
Nº districts with DTP3 coverage >=80% number 12       
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number        
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes    Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes    Yes       

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes    Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.